PLOD1 and ovarian hyperstimulation syndrome: The use of pre-treatment biomarkers to personalize exogenous gonadotrophin doses, gonadotrophin-releasing hormone (GnRH) antagonists to prevent premature luteinizing hormone (LH) surges, the transition from human chorionic gonadotrophin (hCG) to GnRH agonists to induce an endogenous LH surge, and cycle segmentation by temporally separating stimuli have all been implemented. However, failure to adequately execute these techniques can lead to ovarian hyperstimulation syndrome (OHSS) [14].